Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study

被引：3

作者：

Rezazadeh, Alexandra ^{[1
]}

Szabo, Aniko ^{[1
]}

Khurana, Arushi ^{[2
]}

Inwards, David J. ^{[2
]}

Lunning, Matthew A. ^{[3
]}

Bartlett, Nancy L. ^{[4
]}

Caimi, Paolo F. ^{[5
]}

Rodgers, Thomas D. ^{[6
]}

Barr, Paul M. ^{[6
]}

Chowdhury, Sayan Mullick ^{[7
]}

Epperla, Narendranath ^{[7
]}

Mendries, Hiruni ^{[8
]}

Hill, Brian T. ^{[8
]}

Oh, Timothy S. ^{[9
]}

Karmali, Reem ^{[9
]}

Chang, Julie E. ^{[1
,10
]}

Goyal, Gaurav ^{[1
,11
]}

Parsons, Benjamin M. ^{[1
,2
,12
]}

Isaac, Krista M. ^{[1
,3
,13
]}

Portell, Craig A. ^{[1
,3
,13
]}

Monahan, Kathleen ^{[1
]}

Siker, Malika ^{[1
]}

King, David M. ^{[1
]}

Fenske, Timothy S. ^{[1
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Nebraska, Lincoln, NE USA

[4] Washington Univ, St Louis, MO USA

[5] Case Western, Cleveland, OH USA

[6] Univ Rochester, Rochester, NY USA

[7] Ohio State Univ, Mansfield, OH USA

[8] Cleveland Clin, Cleveland, OH USA

[9] Northwestern Univ, Evanston, IL USA

[10] Univ Wisconsin Madison, Madison, WI USA

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] Gundersen Hlth Syst, Wisconsin Rapids, WI USA

[13] Univ Virginia, Charlottesville, VA USA

来源：

HAEMATOLOGICA | 2024年 / 109卷 / 05期

关键词：

FIELD RADIOTHERAPY; PROGNOSTIC-FACTORS; CHOP CHEMOTHERAPY; RADIATION-THERAPY; ELDERLY-PATIENTS; CYCLES;

D O I：

10.3324/haematol.2023.283210

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT confers additional benefit following rituximab-based chemoimmunotherapy (CIT) induction in patients with limited stage disease. We conducted a multicenter, retrospective analysis of patients treated between 2005 and 2019 using rituximab-based CIT regimens with or without consolidative RT to discern whether consolidative RT adds benefit in patients with stage I-II disease that could be encompassed in one radiation field. A total of 112 patients were included: 78 received CIT and radiation (RT group), and 34 received CIT alone (no RT group). The overall survival at 10 years was 77.9% in the RT group and 89.0% in the no RT group (P=0.42). The relapse-free survival at 10 years was 73.5% in the RT group and 80.3% in the no RT group (P=0.88). Neither improved overall survival nor relapse-free survival was associated with the addition of consolidative RT. Subgroup analysis of patients only achieving a partial response after CIT suggests that these patients may benefit from consolidative RT.

引用

页码：1439 / 1444

页数：6